| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Date of Report (Date of earliest event reported): November 16, 2026 |
| 12 Nov 2026 |
8-K: Regulation FD Disclosure
Traws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID® |
| 23 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of October 23, 2026 (this “Agreement”), by and between Roth Principal Investments, LLC, a Delaware limited liability company (the “Investor”), and Traws Pharma, Inc., a Del... |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study |
| 31 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On July 29, 2026, Traws Pharma, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for... |
| 10 Jul 2026 |
8-K: Other Events
We have acted as counsel to Traws Pharma, Inc., a Delaware corporation (the “Company”), in connection with the offering and sale (the “Offering”) of shares of common stock of the Company, par value $0.01 per share, with an aggregate publ... |
| 09 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Effective as of November 21, 2025, Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.) (the “Company”) established the Traws Pharma, Inc. 2021 Incentive Compensation Plan (the “Plan”). By adoption of this instrument, the Company now d... |
| 22 Jun 2026 |
8-K: Regulation FD Disclosure
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceed |
| 12 Jun 2026 |
8-K: Regulation FD Disclosure
NEWTOWN, PA — June 12, 2026 — (GLOBENEWSWIRE) Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test ... |
| 27 May 2026 |
8-K: Regulation FD Disclosure
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa |
| 26 May 2026 |
8-K: Other Events
We have acted as counsel to Traws Pharma, Inc., a Delaware corporation (the “Company”), in connection with the offering and sale (the “Offering”) of shares of common stock of the Company, par value $0.01 per share, with an aggregate publ... |
| 15 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 |
| 15 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity, |
| 15 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of April 15 2026, by and among Traws Pharma, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, a... |
| 19 Feb 2026 |
8-K: Other Events
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza |
| 26 Jan 2026 |
8-K: Other Events
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza |
| 13 Jan 2026 |
8-K: Other Events
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients |
| 17 Dec 2025 |
8-K: Other Events
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients |
| 16 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 28 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(As amended and restated, effective on the Restatement Effective Date) |
Loading...